Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY)

Historical Holders from Q2 2015 to Q3 2025

Symbol
ADAPY on OTC
Type / Class
Equity / Ordinary Shares, par value GBP 0.001 per share
Shares outstanding
1,571,428,571
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
42,101,464
Holdings value
$5,465,824
% of all portfolios
0%
Number of holders
54
Number of buys
20
Number of sells
-35
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAILLIE GIFFORD & CO 4.6% $19,146,934 70,914,570 BAILLIE GIFFORD & CO 31 Dec 2024
EcoR1 Capital, LLC 4.2% $6,600,000 66,000,000 EcoR1 Capital, LLC 15 Aug 2025
Long Focus Capital Management, LLC 8% $5,533,486 20,494,393 LONG FOCUS CAPITAL MANAGEMENT, LLC 31 Dec 2024
New Enterprise Associates 14, L.P. 0% $0.4 4 New Enterprise Associates 14, L.P. 15 Aug 2025

Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 42,101,464 $5,465,824 -$18,296,183 $0.13 54
2025 Q2 115,567,681 $27,687,316 -$90,777 $0.2397 62
2025 Q1 116,071,575 $22,853,519 -$8,159,230 $0.197 66
2024 Q4 124,428,941 $67,025,039 -$30,501,887 $0.5387 79
2024 Q3 151,690,402 $144,141,106 -$2,309,667 $0.9504 79
2024 Q2 153,890,194 $150,022,429 -$8,879,193 $0.9749 75
2024 Q1 162,072,769 $256,066,400 +$30,563,845 $1.58 77
2023 Q4 143,571,040 $113,849,906 -$3,752,852 $0.793 76
2023 Q3 148,301,336 $115,679,142 +$2,660,882 $0.78 77
2023 Q2 144,690,313 $133,837,483 +$26,555,200 $0.925 85
2023 Q1 115,955,853 $126,383,143 +$2,091,094 $1.09 62
2022 Q4 113,878,984 $166,253,761 +$537,924 $1.46 64
2022 Q3 113,851,192 $122,380,454 -$1,743,981 $1.08 60
2022 Q2 114,736,783 $195,049,662 +$7,481,032 $1.7 71
2022 Q1 108,766,325 $224,054,046 -$22,141,212 $2.06 74
2021 Q4 113,574,015 $425,913,139 -$9,027,809 $3.75 81
2021 Q3 111,668,173 $577,323,373 +$3,505,834 $5.17 91
2021 Q2 111,675,475 $475,734,700 -$26,231,441 $4.26 80
2021 Q1 117,483,515 $623,821,340 -$3,868,785 $5.31 80
2020 Q4 118,175,702 $636,961,652 -$92,063,137 $5.39 86
2020 Q3 129,788,880 $1,035,562,966 +$4,544,653 $7.98 75
2020 Q2 128,234,852 $1,283,635,211 +$368,627,077 $10.01 75
2020 Q1 93,844,355 $255,255,329 +$79,458,201 $2.72 45
2019 Q4 64,873,900 $77,850,537 -$4,188,215 $1.2 36
2019 Q3 68,106,153 $102,837,183 -$1,396,792 $1.51 41
2019 Q2 68,202,423 $274,163,898 -$5,115,557 $4.02 54
2019 Q1 69,361,079 $298,254,029 -$2,011,560 $4.3 62
2018 Q4 69,110,505 $397,336,060 -$4,292,035 $5.75 74
2018 Q3 65,498,777 $887,959,093 +$131,556,420 $13.56 89
2018 Q2 55,906,827 $663,498,251 -$2,398,948 $11.87 86
2018 Q1 56,164,712 $630,580,601 +$52,080,454 $11.23 74
2017 Q4 52,069,135 $347,598,008 +$7,236,337 $6.68 68
2017 Q3 50,808,497 $415,724,914 +$29,078,237 $8.19 65
2017 Q2 48,136,079 $215,672,000 +$37,543,838 $4.49 52
2017 Q1 39,767,515 $218,557,000 +$55,023,373 $5.51 48
2016 Q4 29,816,999 $120,746,000 -$7,125,584 $4.05 39
2016 Q3 30,948,897 $218,188,000 -$7,902,917 $7.05 46
2016 Q2 31,884,613 $259,855,000 -$981,225 $8.15 47
2016 Q1 32,005,599 $260,222,000 +$87,357,587 $8.13 48
2015 Q4 20,810,197 $250,066,000 +$67,529,076 $12.06 48
2015 Q3 15,161,949 $181,487,000 -$67,512,067 $11.97 41
2015 Q2 20,950,250 $384,020,000 +$375,243,000 $18.33 45